• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Shuttle Pharmaceuticals Holdings Inc.

    5/15/26 4:45:23 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SHPH alert in real time by email
    Form D
    FORM D
    Notice of Exempt Offering of Securities

    UNITED STATES SECURITIES
    AND EXCHANGE COMMISSION
    Washington, D.C.

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated Average burden hours per response: 4.0
    1. Issuer's Identity
    CIK (Filer ID Number)Previous Name(s)Checkbox checkedNoneEntity Type
    0001757499
    Radio button checkedCorporation
    Radio button not checked Limited Partnership
    Radio button not checked Limited Liability Company
    Radio button not checked General Partnership
    Radio button not checked Business Trust
    Radio button not checkedOther 
    Name of Issuer
     Shuttle Pharmaceuticals Holdings, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE 
    Year of Incorporation/Organization
    Radio button checkedOver Five Years Ago
    Radio button not checkedWithin Last Five Years (Specify Year)
     
    Radio button not checkedYet to Be Formed
     
      
      
     
    2. Principal Place of Business and Contact Information
    Name of Issuer
     Shuttle Pharmaceuticals Holdings, Inc.
    Street Address 1Street Address 2
     401 PROFESSIONAL DRIVE
     SUITE 260
    CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
     GAITHERSBURG
     MARYLAND
     
     20879
     (240) 403-4212 




    3. Related Persons

    Last NameFirst NameMiddle Name
    Cooper
    Christopher
    Street Address 1Street Address 2
     401 PROFESSIONAL DRIVE 
     SUITE 260
    CityState/Province/CountryZIP/Postal Code
     GAITHERSBURG
     MARYLAND
     20879
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    Co-Chief Executive Officer



    Last NameFirst NameMiddle Name
    Scorsis
    George
    Street Address 1Street Address 2
     401 PROFESSIONAL DRIVE 
     SUITE 260
    CityState/Province/CountryZIP/Postal Code
     GAITHERSBURG
     MARYLAND
     20879
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Chambers
    Adam
    Street Address 1Street Address 2
     401 PROFESSIONAL DRIVE 
     SUITE 260
    CityState/Province/CountryZIP/Postal Code
     GAITHERSBURG
     MARYLAND
     20879
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Liang
    Yuying
    Street Address 1Street Address 2
     401 PROFESSIONAL DRIVE 
     SUITE 260
    CityState/Province/CountryZIP/Postal Code
     GAITHERSBURG
     MARYLAND
     20879
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    Chief Financial Officer



    Last NameFirst NameMiddle Name
    Liriano
    Angel
    Street Address 1Street Address 2
     401 PROFESSIONAL DRIVE 
     SUITE 260
    CityState/Province/CountryZIP/Postal Code
     GAITHERSBURG
     MARYLAND
     20879
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Trasolini
    Ryan
    Street Address 1Street Address 2
     401 PROFESSIONAL DRIVE 
     SUITE 260
    CityState/Province/CountryZIP/Postal Code
     GAITHERSBURG
     MARYLAND
     20879
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    Co-Chief Executive Officer





    4. Industry Group
     Radio button not checkedAgriculture
    Banking & Financial Services
     Radio button not checked Commercial Banking
     Radio button not checked Insurance
     Radio button not checkedInvesting
     Radio button not checked Investment Banking
     Radio button not checked Pooled Investment Fund

     Radio button not checkedOther Banking & Financial Services
    Radio button not checked Business Services
    Energy
     Radio button not checked Coal Mining
     Radio button not checked Electric Utilities
     Radio button not checked Energy Conservation
     Radio button not checked Environmental Services
     Radio button not checked Oil & Gas
     Radio button not checked Other Energy
    Health Care
     Radio button not checked Biotechnology
     Radio button not checked Health Insurance
     Radio button not checked Hospitals & Physicians
     Radio button not checked Pharmaceuticals
     Radio button not checked Other Health Care
       
       
       
      
    Radio button not checked Manufacturing
    Real Estate
     Radio button not checkedCommercial
     Radio button not checkedConstruction
     Radio button not checkedREITS & Finance
     Radio button not checkedResidential
    Radio button not checkedOther Real Estate
    Radio button not checked Retailing
    Radio button not checkedRestaurants
    Technology
    Radio button not checked Computers
    Radio button not checked Telecommunications
    Radio button checked Other Technology
    Travel
    Radio button not checked Airlines & Airports
    Radio button not checked Lodging & Conventions
    Radio button not checked Tourism & Travel Services
    Radio button not checked Other Travel
    Radio button not checkedOther

      
       
    5. Issuer Size
    Revenue RangeAggregate Net Asset Value Range
    Radio button not checkedNo RevenuesRadio button not checked No Aggregate Net Asset Value
    Radio button not checked $1 - $1,000,000Radio button not checked$1 - $5,000,000
    Radio button not checked $1,000,001 - $5,000,000Radio button not checked $5,000,001 - $25,000,000
    Radio button not checked$5,000,001 - $25,000,000Radio button not checked $25,000,001 - $50,000,000
    Radio button not checked$25,000,001 - $100,000,000Radio button not checked $50,000,001 - $100,000,000
    Radio button not checked Over $100,000,000Radio button not checked Over $100,000,000
    Radio button checked Decline to Disclose Radio button not checkedDecline to Disclose
    Radio button not checked Not ApplicableRadio button not checked Not Applicable

     
    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
    Checkbox not checkedRule 504(b)(1) (not (i), (ii)
    or (iii))
    Checkbox checkedRule 506(b)      
    Checkbox not checkedRule 504 (b)(1)(i) Checkbox not checkedRule 506(c)
    Checkbox not checkedRule 504 (b)(1)(ii) Checkbox not checkedSecurities Act Section 4(a)(5)
    Checkbox not checkedRule 504 (b)(1)(iii)Checkbox not checkedInvestment Company Act Section 3(c)
     
     

    7. Type of Filing
    Checkbox checked New Notice Date of First Sale 
    2026-04-30
    Checkbox not checked First Sale Yet to Occur
    Checkbox not checked Amendment


     
     
    8. Duration of Offering
    Does the Issuer intend this offering to last more than one year? Radio button not checked Yes Radio button checked No
     
     
    9. Type(s) of Securities Offered (select all that apply)
    Checkbox not checkedPooled Investment Fund InterestsCheckbox checkedEquity
    Checkbox not checkedTenant-in-Common Securities Checkbox not checkedDebt
    Checkbox not checkedMineral Property SecuritiesCheckbox checkedOption, Warrant or Other Right to Acquire Another Security
    Checkbox checkedSecurity to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire SecurityCheckbox not checkedOther (describe)
     
     
     
    10. Business Combination Transaction
    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Radio button checked Yes Radio button not checked No
    Clarification of Response (if Necessary)
    The private placement (PIPE) financing closed concurrently with a Merger transaction of the issuer's wholly owned subsidiary and United Dogecoin, Inc.
     
     
    11. Minimum Investment
    Minimum investment accepted from any outside investor$
     0
    USD

    12. Sales Compensation
    Recipient Recipient CRD NumberCheckbox not checkedNone
     E.F. Hutton & Co.
     000322687
    (Associated) Broker or DealerCheckbox checkedNone(Associated) Broker or Dealer CRD Number Checkbox checkedNone
      
      
    Street Address 1      Street Address 2
    745 5TH Ave
    34th FL
    City State/Province/CountryZIP/Postal Code
     New York
     NEW YORK
     10151
    State(s) of SolicitationCheckbox not checkedAll StatesCheckbox not checkedForeign/Non-US
     
    FLORIDA
    NEW YORK




    13. Offering and Sales Amounts
     
    Total Offering Amount $
    9955000
    USDCheckbox not checkedIndefinite
    Total Amount Sold $
    9955000
    USD
    Total Remaining to be Sold $
    0
    USDCheckbox not checkedIndefinite
    Clarification of Response (if Necessary)
      
     
    14. Investors

    Checkbox not checkedSelect if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
    Number of such non-accredited investors who already have invested in the offering
       
      Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    47
     
    15. Sales Commissions & Finders’ Fees Expenses
    Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
    Sales Commissions$
    1034480
    USDCheckbox not checkedEstimate
    Finders' Fees$
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
     
     

    16. Use of Proceeds
    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
     $ 
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
     

    Signature and Submission
     
    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
    Terms of Submission 
     In submitting this notice, each Issuer named above is: 
     
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).
     
    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.
    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.
     
    IssuerSignatureName of SignerTitleDate
    Shuttle Pharmaceuticals Holdings, Inc./s/ Christopher CooperChristopher CooperCo-Chief Executive Officer2026-05-15




    Get the next $SHPH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SHPH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SHPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Trasolini Ryan

    3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)

    6/1/26 7:11:22 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Liang Yuying

    3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)

    1/12/26 4:15:20 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Liriano Angel claimed no ownership of stock in the company (SEC Form 3)

    3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)

    10/29/25 2:05:48 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SHPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Shuttle Pharmaceuticals and United Dogecoin Announce Purchase Order for up to 3,000 ElphaPex Dogecoin and Litecoin Mining Rigs

    Initial Mining Fleet Targeted for Deployment Within 60 Days of Receipt; To Mine DOGE and LTC and Accumulate Mined Coins as Long-Term Treasury AssetsGaithersburg, Maryland--(Newsfile Corp. - May 14, 2026) - Shuttle Pharmaceutical Holdings, Inc. (NASDAQ:SHPH) ("Shuttle" or the "Company") today announced the closing (the "Closing") of its previously announced merger with United Dogecoin Inc. ("United Dogecoin"), and the confirmation of a purchase order granting the Company the option to purchase up to 3,000 next-generation ElphaPex Scrypt mining rigs ("Mining Rigs") for use in the Company's Dogecoin (DOGE) and Litecoin (LTC) merge-mining operations. As previously reported on Shuttle's Current R

    5/14/26 4:05:00 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    E.F. Hutton & Co. Serves as Exclusive M&A Advisor and Placement Agent on Completed Shuttle Pharmaceuticals–United Dogecoin Merger to Create the Largest Public Dogecoin Miner

    NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. ("E.F. Hutton"), a leading investment banking and financial advisory firm, today announced it served as exclusive M&A advisor and placement agent in connection with the successful closing of Shuttle Pharmaceuticals Holdings, Inc.'s (NASDAQ:SHPH) acquisition of United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining company driven by industry experts. The transaction, completed pursuant to a definitive merger agreement, resulted in United Dogecoin merging into a wholly owned subsidiary of Shuttle Pharmaceuticals, creating one of the largest publicly traded Dogecoin mining platforms. In connection with the mer

    5/7/26 2:02:34 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shuttle Merges with United Dogecoin to Become the World's Largest Public Dogecoin Miner

    The combination and related financing is expected to result in the largest publicly listed Dogecoin mining company based on percentage of the global hashrateGaithersburg, Maryland--(Newsfile Corp. - April 30, 2026) - Shuttle Pharmaceutical Holdings, Inc. (NASDAQ:SHPH) ("Shuttle") has entered into a definitive merger agreement to acquire United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining company driven by industry experts. United Dogecoin will be merged into a wholly owned subsidiary of Shuttle. The merger is supported by a $11 million concurrent Private Investment in Public Equity ("PIPE") financing expected to close on May 4, 2026. United Dogecoin's competitive adv

    4/30/26 4:05:00 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SHPH
    SEC Filings

    View All

    Shuttle Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

    5/27/26 9:00:14 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by Shuttle Pharmaceuticals Holdings Inc.

    D - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

    5/15/26 4:45:23 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Shuttle Pharmaceuticals Holdings Inc.

    10-Q - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

    5/15/26 4:31:42 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SHPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Shuttle Pharmaceuticals Holdings Inc. (Amendment)

    SC 13G/A - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Subject)

    10/17/23 6:57:47 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Shuttle Pharmaceuticals Holdings Inc.

    SC 13G - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Subject)

    5/30/23 5:30:57 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SHPH
    Leadership Updates

    Live Leadership Updates

    View All

    Shuttle Pharmaceuticals Acquires AI Health Platform

    Rockville, Maryland--(Newsfile Corp. - November 21, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle" or the "Company") today announced that it has closed the acquisition of the assets and liabilities of 1542770 B.C. Ltd. d/b/a Molecule.ai ("Molecule"), a Canadian artificial intelligence company specializing in molecular discovery and drug development technologies.Under the terms of the agreement, 1563868 B.C. Ltd., a wholly owned subsidiary of Shuttle, acquired substantially all of Molecule's assets and liabilities for a total purchase price of $8 million, payable in a combination of cash and shares of Shuttle common stock, plus an additional contingent $2 million, pay

    11/21/25 9:30:00 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

    GAITHERSBURG, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of George Scorsis as the Chairman of the Board of Directors. Mr. Scorsis has served as director of the Company since February 2025. Mr. Scorsis has over 25 years of experience leading companies in highly regulated industries to rapid growth, including alcohol, energy drinks, and Biotech. From October 2015 to July 2017, Mr. Scorsis worked as President at Mettrum Heal

    6/4/25 4:01:00 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

    GAITHERSBURG, Md., March 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of Christopher Cooper as interim Co-Chief Executive Officer focused on enhancing the Company's capital markets and business capabilities. Dr. Anatoly Dritschilo, Chairman of the Company's Board of Directors, will continue in his role as Co-CEO overseeing the Company's scientific and clinical trial activities. "I am excited to welcome Christopher Cooper as Co-CEO of

    3/12/25 6:20:00 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care